NASDAQ
90.00USD
0.00 (0.00%)
We have scored 8 news catalysts on Merus N.V. (MRUS) over the past 12 months. The biggest single-day move next to one of them came Sep 29, 2025, when MRUS closed +36.0%: “Genmab to buy Dutch cancer drugmaker Merus for $8 billion”. Coverage across the window leans positive (average ticker sentiment +0.51). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.8B
P/E
—
EPS
—
Beta
1.06
52W range
33.19-97.14
Day range
90.00–90.00
Open
90.00
Prev close
90.00
Volume
2.7M
Avg volume
1.7M
Dividend
0.00
IPO
2016-05-19
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Merus N.V. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Merus N.V., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for MRUS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158: In Phase 1 clinical trials for solid tumors. MCLA-145: Also in Phase 1 clinical trials for various solid tumors. MCLA-129: Progressing through Phase 1/2 clinical trials for advanced non-small cell lung cancer (NSCLC) and other solid tumors. ONO-4685: Currently in Phase 1 clinical trials to address relapsed/refractory T-cell lymphoma. Furthermore, Merus engages in strategic partnerships. It collaborates with Betta Pharmaceuticals Co. Ltd on the research and development of specific bispecific antibody candidates, including MCLA-129. Additionally, Incyte Corporation is partnering with Merus for the development of MCLA-145.
